Asia Pacific Cell Lysis And Disruption Market Size & Outlook
Asia Pacific cell lysis and disruption market, 2018-2028 (US$M)
Related Markets
Asia Pacific cell lysis and disruption market highlights
- The Asia Pacific cell lysis and disruption market generated a revenue of USD 926.7 million in 2020.
- The market is expected to grow at a CAGR of 11.4% from 2021 to 2028.
- In terms of segment, reagent-based was the largest revenue generating technique in 2020.
- Reagent-based is the most lucrative technique segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2021 to 2028.
Asia Pacific data book summary
| Market revenue in 2020 | USD 926.7 million |
| Market revenue in 2028 | USD 2,195.9 million |
| Growth rate | 11.4% (CAGR from 2020 to 2028) |
| Largest segment | Reagent-based |
| Fastest growing segment | Reagent-based |
| Historical data covered | 2018 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Reagent-based, Physical Disruption |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Rad Laboratories Inc, Roche Holding AG ADR, Qiagen NV, Danaher Corp, Miltenyi Biotec, IDEX Corp, BD, Claremont BioSolutions, Parr Instrument Company, Covaris, Cell Signaling Technology, Qsonica |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.6% of the global cell lysis and disruption market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2028.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,195.9 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Lysis And Disruption Market Scope
Cell Lysis And Disruption Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific cell lysis and disruption market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell lysis and disruption market will help companies and investors design strategic landscapes.
Reagent-based was the largest segment with a revenue share of 62.11% in 2020. Horizon Databook has segmented the Asia Pacific cell lysis and disruption market based on reagent-based, physical disruption covering the revenue growth of each sub-segment from 2018 to 2028.
Asia Pacific is considered the fastest growing region in the global cell lysis & disruption market. Japan and China are the most attractive markets in the region with high investments in precision medicine and omics technologies.
Other Asian countries are also making their moves to compete in the market. Key players in Singapore are taking efforts to make the country a hub for healthcare innovation in Asia, with significant interest in biotechnology.
In addition, continuous reforms in the healthcare and biotechnology sectors in the region would further boost market growth. Large population and untapped potential present in the region have led to shift in businesses of the global firms in this region.
Reasons to subscribe to Asia Pacific cell lysis and disruption market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific cell lysis and disruption market databook
-
Our clientele includes a mix of cell lysis and disruption market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific cell lysis and disruption market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific cell lysis and disruption market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific cell lysis and disruption market size, by country, 2018-2028 (US$M)
Asia Pacific Cell Lysis And Disruption Market Outlook Share, 2020 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
